VISION H2020 Project
Published November 2, 2022 | Version v1
Journal article Open

Liquid biopsy and preclinical tools for advancing diagnosis and treatment of patients with pancreatic neuroendocrine neoplasms

Creators

  • 1. Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, Slovakia; Correspondence to: Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, Slovakia;
  • 2. 1st Department of Propaedeutic Surgery, National and Kapodistrian University of Athens, Vasilissis Sofias 114, 11527 Athens, Greece
  • 3. Molecular Epidemiology and Predictive Tumor Markers Group, Medical Oncology Research Laboratory, Ram´on y Cajal Health Research Institute (IRYCIS), CIBERONC, Carretera Colmenar Km 9100, Madrid 28034, Spain
  • 4. Pathology Department, Hospital Universitario Ram´on y Cajal, IRYCIS, Carretera Colmenar Km 9100, 28034 Madrid, Spain
  • 5. Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, Slovakia
  • 6. BQC Redox Technologies, Edificio CEEI - Parque Tecnol´ogico de Asturias, 33428 Llanera, Spain
  • 7. Latvian Biomedical Research and Study Centre, Ratsupites str 1-k1, Riga LV-1067, Latvia
  • 8. Department of Medicine, Klinikum Nordfriesland, Erichsenweg 16, 25813 Husum, Germany; Department of Medicine, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
  • 9. Department Bioprocessing & Bioanalytics, Fraunhofer Institute for Biomedical Engineering IBMT, 66280 Sulzbach, Germany

Description

Pancreatic neuroendocrine neoplasms (pNENs) are rare cancers with broad challenges for their management. The main clinical obstacles are the high rate of patients diagnosed at advanced stages, lack of prognostic markers for early detection of disease recurrence in resected patients, significant limitations in identifying those who will benefit from adjuvant therapy, and timely recognition of treatment response. Therefore, the discovery of new prognostic and predictive markers is necessary for patient stratification and clinical management. Liquid biopsy, which has revolutionized the field of clinical oncology, is extremely under-investigated in pNENs. This review highlights its potential and the recent advances in related technologies, as candidates for the delivery of the new tools that can help to refine pNEN diagnosis and to personalize treatment. In addition, the opportunities and limitations of available preclinical research models with regard to biomarker research are discussed in light of pNEN clinical needs.

Notes

The authors acknowledge the Latvian Biomedical Research and Study Centre as well as the Genome Database of the Latvian Population for providing infrastructure and support. This research has received funding from the TRANSCAN-2 program ERA-NET JTC 2017 "Translational research on rare cancers" within the project NExT (Federal Ministry of Education and Research, Germany/ 01KT1910; Slovak Academy of Sciences, Slovakia/ NExT-0711; The Foundation for the support of the Applied Scientific Research and Technology in Asturias, Spain/ IDI/2019/000002; Ministry of Education, Research and Religious Affairs - General Secretariat for Research and Technology, Greece/ Τ9ЕРА3-00012; State Education Development Agency, Latvia/ 1.1.1.5/ ERANET/20/03) and from the European Union's Horizon 2020 research and innovation program under grant agreement No 857381 / VISION, the Spanish Biomedical Research Network in Cancer CIBERONC (CB16/12/00446) and from the Slovak Research and Development Agency (APVV-21-0197, APVV-20-0143).

Files

doi_org101016j_critrevonc_2022_103865.pdf

Files (4.9 MB)

Name Size Download all
md5:727380cb504172763e67cfbeb888b3dc
4.9 MB Preview Download

Additional details

Funding

VISION – Strategies to strengthen scientific excellence and innoVation capacIty for early diagnoSIs of gastrOintestinal caNcers 857381
European Commission